aluates Reports

$ 0.0

Automative

Global HCC (Hepatocellular Carcinoma) Biomarker Market Research Report 2024

Published Date: March 2024

Report Code: QYRE-Auto-16M16719

BUY CHAPTERS

Global HCC (Hepatocellular Carcinoma) Biomarker Market Research Report 2024

Code: QYRE-Auto-16M16719

Report

March 2024

Pages:87

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

HCC

Fujifilm

Eli Lilly and Company

Fujirebio

Roche Diagnostics

Fapon Biotech

LabCorp

Thermo Fisher Scientific

Abcam

Bio-Techne

MyBioSource

RayBiotech

Cusabio

Elabscience Biotechnology

Abbexa

HCC (Hepatocellular Carcinoma) Biomarker Market Size

Biomarker market was valued at US$ 842 million in 2023 and is anticipated to reach US$ 1279.7 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.

HCC (Hepatocellular Carcinoma) Biomarker Market

Hepatocellular carcinoma (HCC) is the seventh most common cancer diagnosis worldwide with high associated mortality. HCC is a unique malignancy, as it typically arises in the setting of chronic liver disease in particular cirrhosis, with competing risks of liver failure, contributing to its low 5-year survival rates of 18%–20%. More than half of worldwide HCC-related deaths occur in Asia, due to endemic hepatitis B (HBV) infection. HCC incidence is rising in many Western countries due to the rising prevalence of nonalcoholic fatty liver disease, alcohol-related liver disease, and hepatitis C (HCV)-related complications despite the availability of direct acting antiviral therapies. The search for biomarkers in hepatocellular carcinoma continues despite recent approvals for immune checkpoint inhibitor combinations, tyrosine kinase inhibitors [TKIs], and antiangiogenesic agents. Biomarkers can be either predictive or prognostic and the only biomarker that has been used clinically is the prognostic biomarker α-fetoprotein (AFP).

The global HCC (Hepatocellular Carcinoma)

North American market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for HCC (Hepatocellular Carcinoma) Biomarker in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of HCC (Hepatocellular Carcinoma) Biomarker include FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam and Bio-Techne, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for HCC (Hepatocellular Carcinoma) Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HCC (Hepatocellular Carcinoma) Biomarker.

Report Scope

The HCC (Hepatocellular Carcinoma) Biomarker market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HCC (Hepatocellular Carcinoma) Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the HCC (Hepatocellular Carcinoma) Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of HCC (Hepatocellular Carcinoma) Biomarker Market Report

Report Metric	Details
Report Name	HCC (Hepatocellular Carcinoma) Biomarker Market
Accounted market size in 2023	US$ 842 million
Forecasted market size in 2030	US$ 1279.7 million
CAGR	6.2%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Alpha-fetoprotein (AFP) Des-γ-carboxy Prothrombin (DCP) Others
Segment by Application	Hospitals Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam, Bio-Techne, MyBiosource, RayBiotech, CUSABIO, Elabscience Biotechnology, Abbexa
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HCC (Hepatocellular Carcinoma) Biomarker companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is HCC (Hepatocellular Carcinoma) Biomarker Market growing?

Ans: The HCC (Hepatocellular Carcinoma) Biomarker Market witnessing a CAGR of 6.2% during the forecast period 2024-2030.

What is the HCC (Hepatocellular Carcinoma) Biomarker Market size in 2030?

Ans: The HCC (Hepatocellular Carcinoma) Biomarker Market size in 2030 will be US$ 1279.7 million.

Who are the main players in the HCC (Hepatocellular Carcinoma) Biomarker Market report?

Ans: The main players in the HCC (Hepatocellular Carcinoma) Biomarker Market are FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam, Bio-Techne, MyBiosource, RayBiotech, CUSABIO, Elabscience Biotechnology, Abbexa

What are the Application segmentation covered in the HCC (Hepatocellular Carcinoma) Biomarker Market report?

Ans: The Applications covered in the HCC (Hepatocellular Carcinoma) Biomarker Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the HCC (Hepatocellular Carcinoma) Biomarker Market report?

Ans: The Types covered in the HCC (Hepatocellular Carcinoma) Biomarker Market report are Alpha-fetoprotein (AFP), Des-γ-carboxy Prothrombin (DCP), Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Alpha-fetoprotein (AFP)

1.2.3 Des-γ-carboxy Prothrombin (DCP)

1.2.4 Others

1.3 Market by Application

1.3.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Perspective (2019-2030)

2.2 HCC (Hepatocellular Carcinoma) Biomarker Growth Trends by Region

2.2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Region (2019-2024)

2.2.3 HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Region (2025-2030)

2.3 HCC (Hepatocellular Carcinoma) Biomarker Market Dynamics

2.3.1 HCC (Hepatocellular Carcinoma) Biomarker Industry Trends

2.3.2 HCC (Hepatocellular Carcinoma) Biomarker Market Drivers

2.3.3 HCC (Hepatocellular Carcinoma) Biomarker Market Challenges

2.3.4 HCC (Hepatocellular Carcinoma) Biomarker Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Revenue

3.1.1 Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Revenue (2019-2024)

3.1.2 Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Players (2019-2024)

3.2 Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by HCC (Hepatocellular Carcinoma) Biomarker Revenue

3.4 Global HCC (Hepatocellular Carcinoma) Biomarker Market Concentration Ratio

3.4.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by HCC (Hepatocellular Carcinoma) Biomarker Revenue in 2023

3.5 HCC (Hepatocellular Carcinoma) Biomarker Key Players Head office and Area Served

3.6 Key Players HCC (Hepatocellular Carcinoma) Biomarker Product Solution and Service

3.7 Date of Enter into HCC (Hepatocellular Carcinoma) Biomarker Market

3.8 Mergers & Acquisitions, Expansion Plans

4 HCC (Hepatocellular Carcinoma) Biomarker Breakdown Data by Type

4.1 Global HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Type (2019-2024)

4.2 Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Type (2025-2030)

5 HCC (Hepatocellular Carcinoma) Biomarker Breakdown Data by Application

5.1 Global HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Application (2019-2024)

5.2 Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)

6.2 North America HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024)

6.4 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)

7.2 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024)

7.4 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)

8.2 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2019-2024)

8.4 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)

9.2 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024)

9.4 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)

10.2 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024)

10.4 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 FUJIFILM

11.1.1 FUJIFILM Company Detail

11.1.2 FUJIFILM Business Overview

11.1.3 FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.1.4 FUJIFILM Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.1.5 FUJIFILM Recent Development

11.2 Eli Lilly and Company

11.2.1 Eli Lilly and Company Company Detail

11.2.2 Eli Lilly and Company Business Overview

11.2.3 Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.2.4 Eli Lilly and Company Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.2.5 Eli Lilly and Company Recent Development

11.3 Fujirebio

11.3.1 Fujirebio Company Detail

11.3.2 Fujirebio Business Overview

11.3.3 Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.3.4 Fujirebio Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.3.5 Fujirebio Recent Development

11.4 Roche Diagnostics

11.4.1 Roche Diagnostics Company Detail

11.4.2 Roche Diagnostics Business Overview

11.4.3 Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.4.4 Roche Diagnostics Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.4.5 Roche Diagnostics Recent Development

11.5 Fapon Biotech

11.5.1 Fapon Biotech Company Detail

11.5.2 Fapon Biotech Business Overview

11.5.3 Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.5.4 Fapon Biotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.5.5 Fapon Biotech Recent Development

11.6 Labcorp

11.6.1 Labcorp Company Detail

11.6.2 Labcorp Business Overview

11.6.3 Labcorp HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.6.4 Labcorp Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.6.5 Labcorp Recent Development

11.7 Thermo Fisher Scientific

11.7.1 Thermo Fisher Scientific Company Detail

11.7.2 Thermo Fisher Scientific Business Overview

11.7.3 Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.7.4 Thermo Fisher Scientific Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.7.5 Thermo Fisher Scientific Recent Development

11.8 Abcam

11.8.1 Abcam Company Detail

11.8.2 Abcam Business Overview

11.8.3 Abcam HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.8.4 Abcam Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.8.5 Abcam Recent Development

11.9 Bio-Techne

11.9.1 Bio-Techne Company Detail

11.9.2 Bio-Techne Business Overview

11.9.3 Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.9.4 Bio-Techne Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.9.5 Bio-Techne Recent Development

11.10 MyBiosource

11.10.1 MyBiosource Company Detail

11.10.2 MyBiosource Business Overview

11.10.3 MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.10.4 MyBiosource Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.10.5 MyBiosource Recent Development

11.11 RayBiotech

11.11.1 RayBiotech Company Detail

11.11.2 RayBiotech Business Overview

11.11.3 RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.11.4 RayBiotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.11.5 RayBiotech Recent Development

11.12 CUSABIO

11.12.1 CUSABIO Company Detail

11.12.2 CUSABIO Business Overview

11.12.3 CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.12.4 CUSABIO Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.12.5 CUSABIO Recent Development

11.13 Elabscience Biotechnology

11.13.1 Elabscience Biotechnology Company Detail

11.13.2 Elabscience Biotechnology Business Overview

11.13.3 Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.13.4 Elabscience Biotechnology Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.13.5 Elabscience Biotechnology Recent Development

11.14 Abbexa

11.14.1 Abbexa Company Detail

11.14.2 Abbexa Business Overview

11.14.3 Abbexa HCC (Hepatocellular Carcinoma) Biomarker Introduction

11.14.4 Abbexa Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

11.14.5 Abbexa Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

HCC

Fujifilm

Eli Lilly and Company

Fujirebio

Roche Diagnostics

Fapon Biotech

LabCorp

Thermo Fisher Scientific

Abcam

Bio-Techne

MyBioSource

RayBiotech

Cusabio

Elabscience Biotechnology

Abbexa

List of Tables

Table 1. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Alpha-fetoprotein (AFP)

Table 3. Key Players of Des-γ-carboxy Prothrombin (DCP)

Table 4. Key Players of Others

Table 5. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2019-2024)

Table 9. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2025-2030)

Table 11. HCC (Hepatocellular Carcinoma) Biomarker Market Trends

Table 12. HCC (Hepatocellular Carcinoma) Biomarker Market Drivers

Table 13. HCC (Hepatocellular Carcinoma) Biomarker Market Challenges

Table 14. HCC (Hepatocellular Carcinoma) Biomarker Market Restraints

Table 15. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Players (2019-2024)

Table 17. Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HCC (Hepatocellular Carcinoma) Biomarker as of 2023)

Table 18. Ranking of Global Top HCC (Hepatocellular Carcinoma) Biomarker Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by HCC (Hepatocellular Carcinoma) Biomarker Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players HCC (Hepatocellular Carcinoma) Biomarker Product Solution and Service

Table 22. Date of Enter into HCC (Hepatocellular Carcinoma) Biomarker Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Type (2019-2024)

Table 26. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Type (2025-2030)

Table 28. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Application (2019-2024)

Table 30. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Application (2025-2030)

Table 32. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030) & (US$ Million)

Table 47. FUJIFILM Company Detail

Table 48. FUJIFILM Business Overview

Table 49. FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Product

Table 50. FUJIFILM Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 51. FUJIFILM Recent Development

Table 52. Eli Lilly and Company Company Detail

Table 53. Eli Lilly and Company Business Overview

Table 54. Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Product

Table 55. Eli Lilly and Company Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 56. Eli Lilly and Company Recent Development

Table 57. Fujirebio Company Detail

Table 58. Fujirebio Business Overview

Table 59. Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Product

Table 60. Fujirebio Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 61. Fujirebio Recent Development

Table 62. Roche Diagnostics Company Detail

Table 63. Roche Diagnostics Business Overview

Table 64. Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Product

Table 65. Roche Diagnostics Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 66. Roche Diagnostics Recent Development

Table 67. Fapon Biotech Company Detail

Table 68. Fapon Biotech Business Overview

Table 69. Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Product

Table 70. Fapon Biotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 71. Fapon Biotech Recent Development

Table 72. Labcorp Company Detail

Table 73. Labcorp Business Overview

Table 74. Labcorp HCC (Hepatocellular Carcinoma) Biomarker Product

Table 75. Labcorp Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 76. Labcorp Recent Development

Table 77. Thermo Fisher Scientific Company Detail

Table 78. Thermo Fisher Scientific Business Overview

Table 79. Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Product

Table 80. Thermo Fisher Scientific Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 81. Thermo Fisher Scientific Recent Development

Table 82. Abcam Company Detail

Table 83. Abcam Business Overview

Table 84. Abcam HCC (Hepatocellular Carcinoma) Biomarker Product

Table 85. Abcam Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 86. Abcam Recent Development

Table 87. Bio-Techne Company Detail

Table 88. Bio-Techne Business Overview

Table 89. Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Product

Table 90. Bio-Techne Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 91. Bio-Techne Recent Development

Table 92. MyBiosource Company Detail

Table 93. MyBiosource Business Overview

Table 94. MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Product

Table 95. MyBiosource Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 96. MyBiosource Recent Development

Table 97. RayBiotech Company Detail

Table 98. RayBiotech Business Overview

Table 99. RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Product

Table 100. RayBiotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 101. RayBiotech Recent Development

Table 102. CUSABIO Company Detail

Table 103. CUSABIO Business Overview

Table 104. CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Product

Table 105. CUSABIO Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 106. CUSABIO Recent Development

Table 107. Elabscience Biotechnology Company Detail

Table 108. Elabscience Biotechnology Business Overview

Table 109. Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Product

Table 110. Elabscience Biotechnology Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 111. Elabscience Biotechnology Recent Development

Table 112. Abbexa Company Detail

Table 113. Abbexa Business Overview

Table 114. Abbexa HCC (Hepatocellular Carcinoma) Biomarker Product

Table 115. Abbexa Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)

Table 116. Abbexa Recent Development

Table 117. Research Programs/Design for This Report

Table 118. Key Data Information from Secondary Sources

Table 119. Key Data Information from Primary Sources

List of Figures

Figure 1. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Type: 2023 VS 2030

Figure 3. Alpha-fetoprotein (AFP) Features

Figure 4. Des-γ-carboxy Prothrombin (DCP) Features

Figure 5. Others Features

Figure 6. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Application: 2023 VS 2030

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Others Case Studies

Figure 11. HCC (Hepatocellular Carcinoma) Biomarker Report Years Considered

Figure 12. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region: 2023 VS 2030

Figure 15. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Players in 2023

Figure 16. Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HCC (Hepatocellular Carcinoma) Biomarker as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by HCC (Hepatocellular Carcinoma) Biomarker Revenue in 2023

Figure 18. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2019-2030)

Figure 20. United States HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2019-2030)

Figure 24. Germany HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2019-2030)

Figure 32. China HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2019-2030)

Figure 40. Mexico HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2019-2030)

Figure 44. Turkey HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. FUJIFILM Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 47. Eli Lilly and Company Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 48. Fujirebio Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 49. Roche Diagnostics Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 50. Fapon Biotech Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 51. Labcorp Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 52. Thermo Fisher Scientific Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 53. Abcam Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 54. Bio-Techne Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 55. MyBiosource Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 56. RayBiotech Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 57. CUSABIO Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 58. Elabscience Biotechnology Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 59. Abbexa Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Alpha Fetoprotein AFP Biomarker Market Research Report 2024

Global Hepatocellular Carcinoma Targeted Drug Market Research Report 2025

Global Hepatoma Cell Targeted Drug Market Research Report 2025

Hepatocellular Carcinoma Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Liver Cancer Molecular Diagnostics Market Research Report 2024

Global Liver Cancer Therapeutics Market Insights Forecast to 2030

Liver Cancer Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hepatocellular Carcinoma Monoclonal Antibody Market Research Report 2025

Global Unresectable Hepatocellular Carcinoma Treatment Market Research Report 2024

Global Liver Cancer Treatment Drug Market Research Report 2025

Global Diagnostic Biomarker Market Research Report 2024

Non Alcoholic Steatohepatitis Biomarkers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Advanced Liver Cancer Treatment Drugs Market Research Report 2024

Liver Cancer Diagnostic Tests Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non alcoholic Steatohepatitis NASH Biomarkers Market Research Report 2024

Global Clinical Biomarker Testing Market Research Report 2024

Global Commercializing Biomarkers Market Research Report 2025

Global Clinical Biomarkers Market Research Report 2024

Global Mouse Model Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions